Scientists have successfully used the first bioengineered bone marrow model to carry out cancer research, offering a new method which does not rely on animal models. The breakthrough, made by researchers at the University of Glasgow, represents an important step forward in being able to uncover insights into leukaemia without the… Read More
3D spheroid models and live-cell analysis – powerful tools transforming drug discovery and cancer science! Download the eBook to learn: How real-time imaging unlocks deeper insights Discover why 3D models outperform traditional cultures How to create more reliable, clinically relevant cancer models Download now and accelerate your breakthroughs. … Read More
Antibody-drug conjugates (ADCs) offer a targeted approach to cancer treatment, combining the specificity of antibodies with the potency of cytotoxic drugs, and have shown promise in improving patient outcomes. This eBook, sponsored by Abzena, explores the latest developments in the ADC field and the opportunities presented by next generation bioconjugates. Read More
The first patients have been dosed in a Phase I/II trial of Domain Therapeutics’ DT-7012 targeting CCR8 in solid cancer tumours DT-7012 is a novel immunotherapy candidate designed to selectively deplete intra-tumoural regulatory T cells (Tregs) by targeting CCR8, a receptor predominantly expressed… Read More
GSK has acquired exclusive rights from biotechnology company Syndivia to develop and commercialise an antibody-drug conjugate (ADC) in prostate cancer. The global biopharma company aims to develop the ADC for metastatic castration-resistant prostate cancer (mCRPC), which remains a significant health burden for men. Approximately 1.4… Read More
Janet Sasso, Information Scientist at CAS, provides an overview of the antibody drug conjugate market and its potential in oncology. Antibody-drug conjugates (ADCs) are a class of targeted biopharmaceuticals that combine the potency… Read More
Pharmaceutical company Eli Lilly has announced encouraging results from the Phase III trial of its Verzenio (abemaciclib) treatment for breast cancer. The data shows that two years of adjuvant abemaciclib plus endocrine therapy (ET) reduced the risk of death from breast cancer by 15.8% versus… Read More
3D spheroid models and live-cell analysis – powerful tools transforming drug discovery and cancer science! Download the eBook to learn: How real-time imaging unlocks deeper insights Discover why 3D models outperform traditional cultures How to create more reliable, clinically relevant cancer models Download now and accelerate your breakthroughs. … Read More
Pharmaceutical company Takeda has announced it has entered a global strategic partnership with biotechnology company Innovent Biologics to develop next-generation medicines for cancer tumours. The agreement will see the development, manufacturing and commercialisation of two late-stage oncology medicines, IBI363 and IBI343, worldwide outside of Greater China. IBI63… Read More
Biotechnology company Iksuda Therapeutics has announced positive data from the Phase I study of IKS014 for the treatment of cancer patients with advanced HER2+ solid tumours. IKS014, a human epidermal growth factor receptor 2 (HER2)-directed ADC, resulted in anti-tumour activity across all dose levels in various tumour… Read More
Tim Sharpington, Chief Executive Officer at Microbiotica… Read More
Scientists have identified a set of ‘signature’ genes that can determine the success of immune cells inside cancer tumours. Research published in Nature Communications reveals that scientists at the University of Tokyo, Japan identified whether CD8+ T cells, a type of immune cell, will multiply… Read More
Accelerate your CAR-T research. Discover high-throughput imaging innovations for assessing cytotoxicity, T cell activation, and proliferation across 2D/3D models. Get proven methods and actionable insights to optimise constructs and scale up your translational assays. You will learn: Ways to evaluate immune cell behavior and function Practical strategies for… Read More
Biotechnology company Amphista Therapeutics has announced its nomination of AMX-883 as its first clinical development candidate for the treatment of acute myeloid leukaemia (AML). AMX-883 is a potent, selective and orally bioavailable degrader of BRD9. Leveraging Amphista’s Eclipsys platform and proprietary Targeted Glue technology, AMX-883 induces the… Read More
A nanoparticle-based vaccine developed by the University of Massachussets Amherst could effectively prevent melanoma, pancreatic and triple-negative breast cancer, the university reveals. Scientists tested the vaccine in mice, with 88% remaining tumour-free. The results also show that the vaccine reduced, and in some cases prevented, the spread… Read More
Biotechnology company Tubulis has announced it has raised a record $361 million in financing to expand its clinical development of the antibody-drug conjugate (ADC) candidate TUB-040. The financing represents the largest Series C for a European biotechnology company and the largest financing for a private ADC developer… Read More
